Patent ID: 11865082
Assignee: HOFFMANN-LA ROCHE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 13:
14. A therapeutic method for (i) inhibiting tumor growth in a tumor; and/or (ii) enhancing median and/or overall survival of subjects with a tumor, wherein PD-1 is presented on immune cells or in a tumor cell environment, the method comprising administering to a subject a combination therapy comprising (a) a PD-1-targeted IL-2 variant immunocytokine in combination with (b) an antibody which binds to human PD-L1,
wherein the PD-1-targeted IL-2 variant immunocytokine comprises:
i) a heavy chain variable domain VH of SEQ ID NO: 5 and a light chain variable domain VL of SEQ ID NO: 6, and the polypeptide sequence of SEQ ID NO: 2, or
ii) the polypeptide sequences of SEQ ID NO: 7, and SEQ ID NO: 8 and SEQ ID NO: 9, or
iii) the polypeptide sequences of SEQ ID NO: 12, and SEQ ID NO: 13 and SEQ ID NO: 14;

and wherein the antibody which binds to human PD-L1 comprises:
a heavy chain variable domain VH of SEQ ID NO: 19 and a light chain variable domain VL of SEQ ID NO: 20.